Alzheimer’s disease is driven by pathological brain changes that progressively impair memory and cognition, with current treatment options being limited. Advances in early, biomarker-based diagnosis and amyloid-targeting and other disease-modifying approaches are beginning to slow disease progression in clinical studies.